The T-cell inflamed tumor, identified via gene expression profiling, has been associated with improved responses to therapy in melanoma.18 Our investigation into what drives responses in TNBC has revealed similar findings, where it is not only the immune cells present that drive responses but also the presence of key cytokines, the type I and II IFNs. Here, SGCG is linked to melanoma.